Shares of Warner Chilcott (WCRX -1.3%) slip after the company issues mixed FY13 guidance as...


Shares of Warner Chilcott (WCRX -1.3%) slip after the company issues mixed FY13 guidance as sales of its osteoporosis drug Actonel continue to weaken. It now expects total revenue of $2.3B to $2.4B, at the low end of the Street consensus of $2.38B. The company expects its cash net income per share to be in the range of $3.20 to $3.30 per share for the 2013 fiscal year. The Street view is $3.59 per share.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs